Phase II Study of 13-cis-Retinoic Acid in Pediatric Patients with Acute Nonlymphocytic Leukemia—A Pediatric Oncology Group Study

Publisher Website
Google Scholar
Abstract
Summary Forty-one patients with refractory acute non-lymphocytic leukemia (ANLL) in relapse were treated with 13-cis-retinoic acid (cRA) as salvage therapy. The cRA was given as a single oral dose of 100 mg/m2/day for 4 weeks. One patient achieved a complete remission and two patients achieved a partial remission with reduction of the bone marrow blast count from 40 to 20% after the first course. We recommend further study of cRA in combination with other agents in the treatment of ANLL in children.

This publication has 0 references indexed in Scilit: